Curative by Design™

”Science may be better served by a new image of its literature as a vast mosaic
of undiscovered connections, a potential source of countless recombinant ideas –
a world with its own endless frontier.”

Don R. Swanson (Bull Med Libr Assoc 78 page 36. (1990))

illustration of ideas being shared

More information on some of Verik’s High Curative Potential (HCP) Target Proteins

Cancer Germline Antigens (Cancer Testis Antigens) as HCP targets

 

The Verik HCP target cancer germline antigen (CGA) AKAP4 in cancer:

 

Saini S. et al. (2013) A Novel Cancer Testis Antigen, A-Kinase Anchor Protein 4 (AKAP4) Is a Potential Biomarker for Breast Cancer. PLoS ONE 8(2):e57095.

 

Agarwal S, et al. (2013) The Novel Cancer-Testis Antigen A-Kinase Anchor Protein 4 (AKAP4) Is A Potential Target for Immunotherapy of Ovarian Serous Carcinoma. OncoImmunology 2(5):e24270.

 

Agarwal S, et al. (2013) Expression and Humoral Response of A-Kinase Anchoring Protein 4 in Cervical Cancer. Int J Gynecol Cancer 23:650.

 

Gumireddy K. et al. (2015) AKAP4 is a circulating biomarker for non-small cell lung cancer. Oncotarget 6:1.

 

Li H.-M. et al. (2015) Expression and Clinical Significance of A-Kinase Anchor Protein 4 In Lung Adenocarcinoma Tissue. Thoracic Cancer 7:271.

 

Jagadish N. et al. (2016) A Novel Cancer Testis Antigen Target A-Kinase Anchor Protein (AKAP4) for the Early Diagnosis and Immunotherapy of Colon Cancer. OncoImmunology 5(2); e1078965.

 

Li S, et al. (2016) AKAP4 Mediated Tumor Malignancy in Esophageal Cancer. Am J Transl Res 8:597.

 

Kumar V, et al. (2017) Role Of A-Kinase Anchor Protein (AKAP4) in Growth and Survival of Ovarian Cancer Cells. Oncotarget 8:53124.

 

 

 

LUZP4 (HOM-TES-85; CT-8), a CGA and emerging Verik HCP™ cancer target:

 

Tureci O, et al. (2002) A Novel Tumor Associated Leucine Zipper Protein Targeting to Sites of Gene Transcription and Splicing. Oncogene 21:3879.

 

Mischo A, et al. (2006) Prospective Study on the Expression of Cancer Testis Genes and Antibody in 100 Consecutive Patients With Primary Breast Cancer. Int J Cancer 118:696.

LUZP4 is found in 47% of the patients.

 

Viphakone N, et al. (2015) LUZP4 Defines a New mRNA Export Pathway in Cancer Cells. Nuclei Acids Research doi: 10.1093/nar/gkv070

 

 

de Anda-Jauregui G, et al. (2016) Transcriptional Network Architecture of Breast Cancer Molecular Subtypes. Front Physiol 7:568.

Using a network-based approach, the authors identify LUZP4 as a high degree gene in Luminal A, Luminal B and Basal types of breast cancer.

 

 

 

LY6K, a CGA and Verik auxiliary target in cancer:

 

Kong H. et al. (2012) The Regulatory Mechanism of the LY6K Gene Expression in Human Breast Cancer Cells. J Biol Chem 287:38889.

 

Kong HK, et al. (2016) Epigenetic Activation of LY6K Predicts the Presence of Metastasis and Poor Prognosis in Breast Carcinoma. Oncotarget 7:55677.

 

Ishikawa N, et al. (2007) Cancer-Testis Antigen Lymphocyte Antigen 6 Complex Locus K is a Serologic Biomarker and Therapeutic Target for Lung and Esophageal Carcinomas. Cancer Res 67:11601.

 

 

 

 

Gene fusions as anti-tumor targets and a source of neoantigen for T cells

 

Yang W, et al. (2019) Immunogenic Neoantigens Derived From Gene Fusions Stimulate T Cell Responses. Nature Medicine 25:767.

 

 

The Verik HCP™target family NUT (NUTM1) fusions in cancer:

 

French C., (2014) NUT Midline Carcinoma. Nat Rev Cancer 14:149.

 

Dickson BC, et al. (2018) NTUM1 Gene Fusions Characterize a Subset of Undifferentiated Soft Tissue and Visceral Tumors. Am J Sug Pathol 42:636.

 

Stathis A, et al. (2016) Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628 Cancer Discovery 6:1.

 

Sholl LM, et al. (2015) Primary Pulmonary NUT Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterization. J Thorac Oncol 10:951.

 

Alekseyenko AA, et al. (2016) The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains. Genes and Development 29:507.

 

Chau NG, et al. (2016) Intensive Treatment and Survival Outcomes in NUT midline Carcinoma of the Head and Neck. Cancer 122:3632.

 

Diolaiti D, et al. (2018) A Recurrent Novel MGA-NUTM1 Fusion Identifies a New Subtype of High-Grade Spindle Cell Sarcoma. Cold Spring Harb Mol Case Stud 4:a003194.

 

Tamura R, et al. (2018) Novel MXD4-NUTM1 Fusion Transcript Identified in Primary Ovarian Undifferentiated Small Round Cell Sarcoma. Genes Chromosomes Cancer 57:557.

 

Stevens TM, et al. (2019) NUTM1-Rearranged Neoplasia: A Multi-institution Experience Yields Novel Fusion Partners and Expands the Histologic Spectrum. Modern Pathology 32:764.

 

 

Presently, Verik HCP targets include shared, T cell-targetable neoantigens in other gene fusions as well.

 

 

 

© 2019 Verik Bio, Inc